Target intelligence / Profile preview

Plasmodium falciparum cleavage and polyadenylation specificity factor subunit 3 (PfCPSF3) (PfCPSF3)

Target
PfCPSF3
Molecular classification
Enzyme, Endonuclease, Metallohydrolase, Metallo-beta-lactamase fold protein
01

Overview

Plasmodium falciparum cleavage and polyadenylation specificity factor subunit 3 (PfCPSF3) is a 73 kDa zinc-dependent endonuclease that serves as the catalytic core of the CPSF complex in the malaria parasite [1, 6]. It plays an essential role in the 3'-end processing of pre-mRNA by cleaving the transcript downstream of the polyadenylation signal, a prerequisite for polyadenylation and subsequent translation into functional proteins [3, 6]. Because this mRNA maturation process is vital for the survival of P. falciparum across multiple life stages, including the asexual blood stage and liver stage, PfCPSF3 has been identified as a high-priority antimalarial drug target [2, 6]. Small molecule inhibitors, particularly those from the benzoxaborole class such as AN3661 and AN11736, exert potent antimalarial effects by binding to the catalytic site of PfCPSF3 and blocking its enzymatic activity [6, 7]. This inhibition leads to the accumulation of unprocessed mRNA and rapid parasite death, offering a novel mechanism of action that bypasses existing resistance to traditional antimalarials like artemisinin [3, 6]. However, therapeutic development must address the challenge of achieving high selectivity to avoid cross-reactivity with the human CPSF3 ortholog and monitoring for emerging resistance mutations in the parasite's active site [4, 6].

Other names
CPSF3CPSF73CPSF-73mRNA 3'-end-processing endonuclease CPSF3PF3D7_1461800PF14_0364
02

Mechanism of action

Inhibition of the endonuclease activity of the CPSF3 subunit, preventing the cleavage and polyadenylation of pre-mRNA, which leads to the failure of mRNA maturation and subsequent parasite death.

03

Biological functions

mRNA processingPre-mRNA 3'-end cleavagePolyadenylationGene expression regulation
04

Disease associations

InfectionMalaria
05

Safety considerations

Selectivity against the human CPSF3 orthologEmergence of drug-resistant mutations in the catalytic site
06

Interacting drugs

AN3661

3 more in the full profile.

07

Biomarkers

Parasite clearance ratePfCPSF3 active site mutations (e.g., Y408S, Y408H, T406I)Parasite 18S rRNA levels

Beyond the preview

Go deeper on Plasmodium falciparum cleavage and polyadenylation specificity factor subunit 3 (PfCPSF3) (PfCPSF3).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Plasmodium falciparum cleavage and polyadenylation specificity factor subunit 3 (PfCPSF3) (PfCPSF3).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call